The final report of Post-Authorisation Safety Study (PASS), investigating myocarditis and pericarditis following Pfizer-BioNTech mRNA COVID-19 vaccination, has been published in the HMA-EMA Catalogue (EUPAS47708). This publication marks the completion of a major multi-country effort conducted within the VAC4EU collaboration to generate robust real-world evidence on vaccine safety across Europe.
Teamit Institute served as study manager for this PASS, coordinating activities across all participating partners and supporting the delivery of a high-quality, harmonised observational study.
As an active member of VAC4EU, Teamit Institute continues to reinforce the European vaccine monitoring infrastructure by contributing expertise in study management, guidance and business development. The completion of this PASS reflects Teamit’s ongoing commitment to advancing real-world evidence generation and supporting public health through collaborative, data-driven research.
